全文获取类型
收费全文 | 7256篇 |
免费 | 318篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 161篇 |
儿科学 | 130篇 |
妇产科学 | 188篇 |
基础医学 | 880篇 |
口腔科学 | 165篇 |
临床医学 | 499篇 |
内科学 | 1791篇 |
皮肤病学 | 169篇 |
神经病学 | 538篇 |
特种医学 | 147篇 |
外科学 | 1045篇 |
综合类 | 59篇 |
预防医学 | 635篇 |
眼科学 | 181篇 |
药学 | 383篇 |
中国医学 | 31篇 |
肿瘤学 | 605篇 |
出版年
2023年 | 44篇 |
2022年 | 74篇 |
2021年 | 222篇 |
2020年 | 118篇 |
2019年 | 211篇 |
2018年 | 216篇 |
2017年 | 134篇 |
2016年 | 147篇 |
2015年 | 168篇 |
2014年 | 254篇 |
2013年 | 342篇 |
2012年 | 569篇 |
2011年 | 604篇 |
2010年 | 348篇 |
2009年 | 355篇 |
2008年 | 527篇 |
2007年 | 524篇 |
2006年 | 452篇 |
2005年 | 478篇 |
2004年 | 430篇 |
2003年 | 354篇 |
2002年 | 396篇 |
2001年 | 42篇 |
2000年 | 38篇 |
1999年 | 56篇 |
1998年 | 48篇 |
1997年 | 47篇 |
1996年 | 42篇 |
1995年 | 29篇 |
1994年 | 36篇 |
1993年 | 37篇 |
1992年 | 19篇 |
1991年 | 19篇 |
1990年 | 11篇 |
1989年 | 18篇 |
1988年 | 18篇 |
1987年 | 8篇 |
1986年 | 13篇 |
1985年 | 9篇 |
1984年 | 16篇 |
1983年 | 12篇 |
1982年 | 19篇 |
1980年 | 13篇 |
1979年 | 6篇 |
1978年 | 10篇 |
1976年 | 6篇 |
1975年 | 5篇 |
1974年 | 10篇 |
1973年 | 5篇 |
1971年 | 6篇 |
排序方式: 共有7607条查询结果,搜索用时 15 毫秒
81.
82.
The relationship between dietary fat intake and risk of colorectal cancer: evidence from the combined analysis of 13 case-control studies 总被引:3,自引:0,他引:3
Geoffrey R. Howe Kristan J. Aronson Enrique Benito Roberto Castelleto Jacqueline Cornée Stephen Duffy Richard P. Gallagher José M. Iscovich Jiao Deng-ao Rudolf Kaaks Gabriel A. Kune Susan Kune Hin P. Lee Marion Lee Anthony B. Miller Ruth K. Peters John D. Potter Elio Riboli Martha L. Slattery Dimitrios Trichopoulos Albert Tuyns Anastasia Tzonou Lyndsey F. Watson Alice S. Whittemore Anna H. Wu-Williams Zheng Shu 《Cancer causes & control : CCC》1997,8(2):215-228
The objective of this study was to examine the effects of the intakeof dietary fat upon colorectal cancer risk in a combined analysis of datafrom 13 case-control studies previously conducted in populations withdiffering colorectal cancer rates and dietary practices. Original datarecords for 5,287 cases of colorectal cancer and 10,470 controls werecombined. Logistic regression analysis was used to estimate odds ratios (OR)for intakes of total energy, total fat and its components, and cholesterol.Positive associations with energy intake were observed for 11 of the 13studies. However, there was little, if any, evidence of anyenergy-independent effect of either total fat with ORs of 1.00, 0.95, 1.01,1.02, and 0.92 for quintiles of residuals of total fat intake (P trend =0.67) or for saturated fat with ORs of 1.00, 1.08, 1.06, 1.21, and 1.06 (Ptrend = 0.39). The analysis suggests that, among these case-control studies,there is no energy-independent association between dietary fat intake andrisk of colorectal cancer. It also suggests that simple substitution of fatby other sources of calories is unlikely to reduce meaningfully the risk ofcolorectal cancer. 相似文献
83.
84.
Fernando A Crocenzi Vanesa D'Andrea Viviana A Catania Marcelo G Luquita José M Pellegrino J Elena Ochoa Aldo D Mottino Enrique J Sánchez Pozzi 《Drug metabolism and disposition》2005,33(7):888-891
Ethinylestradiol (EE) induces cholestasis by affecting bile salt-dependent and -independent fractions of the bile flow. The decrease in bile salt-independent flow is thought to be due, in part, to a reduction in the expression of the canalicular transporter Mrp2. The impact of modulation of Mrp2 function by sodium ursodeoxycholate (UDC) in EE cholestasis is unknown. We evaluated the protective effect of UDC on EE-induced impairment of Mrp2 activity in vivo and in isolated hepatocytes, by using the substrate dinitrophenyl S-glutathione (DNP-SG). EE was administered to male Wistar rats at a dose of 5 mg/kg s.c. for 5 days. UDC was coadministered with EE at a dose of 25 mg/kg b.wt. i.p. for the same period. EE alone reduced DNP-SG biliary excretion by 55% when compared with controls. Coadministration with UDC partially restored the alteration. Secretion rate of DNP-SG was decreased by 30% in isolated hepatocytes from EE-treated rats, but, contrary to in vivo results, UDC coadministration did not restore DNP-SG transport, likely as a consequence of bile salt washout resulting from the isolation procedure. As a confirmation, tauroursodeoxycholate hepatocyte preloading significantly increased Mrp2 activity. Western blotting analysis of Mrp2 indicated that EE administration significantly reduced its level in total and plasma membranes and that UDC coadministration failed to revert this alteration. In conclusion, UDC improvement in Mrp2 transport activity in vivo likely derived from a direct enhancement of Mrp2 function rather than from a restoration of its expression levels. This provides a novel mechanism explaining the beneficial effects of UDC in EE-induced cholestasis. 相似文献
85.
86.
Enrique Teran Carlos Escudero Sandra Vivero Armando Enriquez Andres Calle 《Hypertension in pregnancy》2004,23(3):303-308
OBJECTIVE: To investigate the intraplatelet cyclic guanosine-3',5'-monophosphate (cGMP) levels during normal pregnancy and preeclampsia. STUDY DESIGN: Pregnant women (n = 15), women with preeclampsia (n = 15), and nonpregnant, normotensive women (n = 15) were included. Intraplatelet cyclic guanosine-3',5'-monophosphate levels were measured by an enzyme-linked immunosorbent assay. RESULTS: Intraplatelet cGMP levels were significantly different among all groups (p < 0.02). The values were higher in normal pregnant women (mean 19.8 SD 2.6 fmol/10(5) platelets) in comparison to nonpregnant women (mean 7.6 SD 0.3 fmol/10(5)platelets; p = 0.001) and women with preeclampsia (mean 11.3 SD 1.8 fmol/10(5) platelets; p = 0.05). Plasma nitric oxide levels did not reveal differences between all groups. CONCLUSIONS: The results of this study in a high-risk Andean population demonstrated that intraplatelet cyclic guanosine-3',5'-monophosphate levels are decreased during preeclampsia compared to normal pregnancy, suggesting a lack in action of nitric oxide. 相似文献
87.
Fernando Arias de la Vega Miguel Angel Domínguez Domínguez Ana Manterola Burgaleta Ruth Vera García Maria Eugenia Echeverría Zabalza Eugenio Oria Mundin Enrique Martínez López Pilar Romero Rojano Elena Villafranca Iture 《Clinical & translational oncology》2005,7(2):60-65
INTRODUCTION: This study aims to asses the effectiveness and toxicity of boost radiotherapy concomitant and concurrent cisplatin for patients with locally advanced head and neck cancer (LAHNC). MATERIAL AND METHODS: There were 30 patients included in a prospective, phase II single-institution trial and of whom, 29 were at AJCC stage IV and 1 at stage III. Treatment consisted of radiotherapy acceleration fractionation with concomitant boost, 72 Gy, and 2 cycles of concomitant cisplatin (20 mg/m2/day continuous infusion; days 1-5 and 29-33). Amifostine, (i.v. 200 mg/m2) was administered to 26 prior to the first fraction of radiotherapy. Endpoints of the study were quality-of-life (QL), overall survival, and local control of disease. RESULTS: Complete response (CR) was achieved in 23 patients (77%), 2 patients had partial response (PR) (7%), 4 had no response (13%), and 1 was not evaluated for response. The 2-year overall survival and loco-regional control were 60% and 56%, respectively. Main toxicity was grade 3 or 4 mucositis in 93% of the patients. QL scores (questionnaire QLQC30; version 3.0) and the HN cancer module QLQ-HN35) showed a worsening in areas related to the treatment e.g. dry mouth, problems stretching the mouth, and sticky saliva. CONCLUSIONS: this combination modality is active, but toxic, in the treatment for LAHNC. Concomitant boost radiotherapy is probably, not the best radiotherapy schema for combining with chemotherapy in LAHNC. 相似文献
88.
Javier Sastre Eugenio Marcuello Bartomeu Masutti Matilde Navarro Silvia Gil Antonio Antón Albert Abad Enrique Aranda Joan Maurel Manuel Valladares Inmaculada Maestu Alfredo Carrato José María Vicent Eduardo Díaz-Rubio 《Journal of clinical oncology》2005,23(15):3545-3551
PURPOSE: Elderly patients constitute a subpopulation with special characteristics that differ from those of the nonelderly and have been underrepresented in clinical trials. This study was performed to determine the efficacy and safety of irinotecan (CPT-11) in combination with fluorouracil (FU) administered as a 48-hour continuous infusion twice a month in elderly patients. PATIENTS AND METHODS: Patients > or = 72 years old with metastatic colorectal cancer, Eastern Cooperative Oncology Group performance status of 0 to 1, no geriatric syndromes, and no prior treatment were treated every 2 weeks with CPT-11 180 mg/m2 plus FU 3,000 mg/m2 in a 48-hour continuous infusion. RESULTS: By intent-to-treat analysis, in 85 assessable patients, the objective response rate was 35% (95% CI, 25% to 46%), and stable disease was 33% (95% CI, 23% to 44%). Median time to progression was 8.0 months (95% CI, 6.0 to 10.0 months), and median overall survival time was 15.3 months (95% CI, 13.8 to 16.9 months). Toxicity was moderate. Grade 3 and 4 neutropenia, diarrhea, and asthenia were observed in 21%, 17%, and 13% of patients, respectively. Only one case of neutropenic fever occurred. There were two toxic deaths, one was a result of grade 4 diarrhea and acute kidney failure, and the other was a result of massive intestinal hemorrhage in the first cycle. The study of prognostic factors did not reveal any predictive factor of response. Response to treatment and baseline lactate dehydrogenase were the main factors conditioning progression-free and overall survival. CONCLUSION: Twice a month continuous-infusion CPT-11 combined with FU is a valid therapeutic alternative for elderly patients in good general condition. 相似文献
89.
90.
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. 总被引:2,自引:0,他引:2
Emiliano Honrado Ana Osorio José Palacios Roger L Milne Lydia Sánchez Orland Díez Alicia Cazorla Kirsi Syrjakoski David Huntsman P?ivi Heikkil? Enrique Lerma Anne Kallioniemi Carmen Rivas William D Foulkes Heli Nevanlinna Javier Benítez 《Journal of clinical oncology》2005,23(30):7503-7511
PURPOSE: Morphologic and immunohistochemical studies of familial breast cancers have identified specific characteristics associated with BRCA1 mutation-associated tumors when compared with BRCA2 and non-BRCA1/2 tumors, but have not identified differences between BRCA2 and non-BRCA1/2 tumors. Because BRCA1 and BRCA2 genes participate in the DNA repair pathway, we have performed an immunohistochemical study with markers related to this pathway to establish the profile of the three groups. MATERIALS AND METHODS: We have studied two tissue microarrays that include 103 familial and 104 sporadic breast tumors, with a panel of DNA repair markers including ATM, CHEK2, RAD51, RAD50, XRCC3, and proliferating cell nuclear antigen. RESULTS: We found more frequent expression of CHEK2 in BRCA1 and BRCA2 tumors than in non-BRCA1/2 and sporadic tumors. We found absence of nuclear expression and presence of cytoplasmic expression of RAD51 in BRCA2 tumors that differentiate them from other familial tumors. We validated these results with a new series of patient cases. The final study with 253 familial patient cases (74 BRCA1, 71 BRCA2, 108 non-BRCA1/2), and 288 sporadic patient cases, has allowed us to confirm our preliminary results. Because BRCA2 tumors present a specific immunohistochemical profile for RAD51 and CHEK2 markers that is different from non-BRCA1/2 tumors, we have built a multivariate model with these markers that distinguish both tumors with an estimated probability of at least 76%. CONCLUSION: Our results suggest that BRCA2 tumors demonstrate more cytoplasmic and less nuclear RAD51 staining, and increased CHEK2 staining. This pattern may distinguish BRCA2 from familial non-BRCA1/2 tumors. 相似文献